Hypopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Hypopharyngeal Cancer pipeline market report provides a comprehensive overview of the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects.
Key Targets in the Hypopharyngeal Cancer Pipeline Drugs Market
In the Hypopharyngeal Cancer pipeline drugs market, the key targets are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, 5′ Nucleotidase, Baculoviral IAP Repeat Containing Protein 2, E3 Ubiquitin Protein Ligase XIAP, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, and Fibroblast Growth Factor Receptor 4.
Hypopharyngeal Cancer Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Hypopharyngeal Cancer Pipeline Drugs Market
Programmed Cell Death Protein 1 Antagonist has the highest number of pipeline products followed by Programmed Cell Death 1 Ligand 1 Inhibitor, 5′ Nucleotidase Inhibitor, Baculoviral IAP Repeat Containing Protein 2 Inhibitor, E3 Ubiquitin Protein Ligase XIAP Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor,Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, and Inducible T Cell Costimulator Agonist.
Hypopharyngeal Cancer Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Hypopharyngeal Cancer Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Hypopharyngeal Cancer pipeline drug market are intravenous, subcutaneous, oral, intravenous drip, intratumor, intralesional, intravesical, intramuscular, topical, intradermal, and intraperitoneal. Intravenous has the maximum number of pipeline products.
Hypopharyngeal Cancer Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Hypopharyngeal Cancer Pipeline Drugs Market
The key molecule types in the Hypopharyngeal Cancer pipeline drugs market are monoclonal antibody, small molecule, subunit vaccine, fusion protein, monoclonal antibody conjugated, mRNA vaccine, oligonucleotide, oncolytic virus, cell therapy, and recombinant protein. Monoclonal Antibody has the highest number of pipeline products.
Hypopharyngeal Cancer Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Hypopharyngeal Cancer Pipeline Drugs Market
The major companies in the Hypopharyngeal Cancer pipeline drugs market are Boehringer Ingelheim International GmbH, Merck & Co Inc, Eisai Co Ltd, Incyte Corp, Akeso Inc, Ascenta Therapeutics Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Genentech USA Inc, GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co Ltd, and Shanghai Junshi Bioscience Co Ltd.
Hypopharyngeal Cancer Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Hypopharyngeal Cancer Pipeline Drugs Market Overview
Key Targets | Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, 5′ Nucleotidase, Baculoviral IAP Repeat Containing Protein 2, E3 Ubiquitin Protein Ligase XIAP, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, and Fibroblast Growth Factor Receptor 4 |
Key Mechanisms of action | Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, 5′ Nucleotidase Inhibitor, Baculoviral IAP Repeat Containing Protein 2 Inhibitor, E3 Ubiquitin Protein Ligase XIAP Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor,Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, and Inducible T Cell Costimulator Agonist |
Key Routes of Administration | Intravenous, Subcutaneous, Oral, Intravenous Drip, Intratumor, Intralesional, Intravesical, Intramuscular, Topical, Intradermal, and Intraperitoneal |
Key Molecule Types | Monoclonal Antibody, Small Molecule, Subunit Vaccine, Fusion Protein, Monoclonal Antibody Conjugated, mRNA Vaccine, Oligonucleotide, Oncolytic Virus, Cell Therapy, and Recombinant Protein |
Major Companies | Boehringer Ingelheim International GmbH, Merck & Co Inc, Eisai Co Ltd, Incyte Corp, Akeso Inc, Ascenta Therapeutics Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Genentech USA Inc, GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co Ltd, and Shanghai Junshi Bioscience Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypopharyngeal Cancer
- The pipeline guide reviews pipeline therapeutics for Hypopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypopharyngeal Cancer therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypopharyngeal Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Hypopharyngeal Cancer
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypopharyngeal Cancer
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypopharyngeal Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Ascenta Therapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
BioAtla Inc
Biomimetix JV LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Checkmate Pharmaceuticals Inc
Compugen Ltd
CSPC Pharmaceutical Group Ltd
Dracen Pharmaceuticals Inc
Eisai Co Ltd
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genexine Inc
Genocea Biosciences Inc
GlaxoSmithKline Plc
I-Mab
Incyte Corp
Innate Pharma SA
IO Biotech Inc
Istari Oncology Inc
Jiangsu Hengrui Medicine Co Ltd
Mabpharm Ltd
Merck & Co Inc
Moderna Inc
Oncolys BioPharma Inc
Ono Pharmaceutical Co Ltd
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Rubius Therapeutics Inc
Sanofi
Scancell Holdings Plc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shattuck Labs Inc
VasGene Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Hypopharyngeal Cancer pipeline drug market?
In the Hypopharyngeal Cancer pipeline drugs market the key targets are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, 5′ Nucleotidase, Baculoviral IAP Repeat Containing Protein 2, E3 Ubiquitin Protein Ligase XIAP, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, and Fibroblast Growth Factor Receptor 4.
-
What are the key mechanisms of action in the Hypopharyngeal Cancer pipeline drugs market?
In the Hypopharyngeal Cancer pipeline drugs market the key mechanisms of action are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, 5′ Nucleotidase Inhibitor, Baculoviral IAP Repeat Containing Protein 2 Inhibitor, E3 Ubiquitin Protein Ligase XIAP Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor,Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, and Inducible T Cell Costimulator Agonist.
-
What are the key routes of administration in the Hypopharyngeal Cancer pipeline drugs market?
The key routes of administration in the Hypopharyngeal Cancer pipeline drug market are Intravenous, Subcutaneous, Oral, Intravenous Drip, Intratumor, Intralesional, Intravesical, Intramuscular, Topical, Intradermal, and Intraperitoneal. Intravenous has the maximum number of pipeline products.
-
What are the key molecule types in the Hypopharyngeal Cancer pipeline drugs market?
The key molecule types in the Hypopharyngeal Cancer pipeline drug market are Monoclonal Antibody, Small Molecule, Subunit Vaccine, Fusion Protein, Monoclonal Antibody Conjugated, mRNA Vaccine, Oligonucleotide, Oncolytic Virus, Cell Therapy, and Recombinant Protein.
-
What are the major companies in the Hypopharyngeal Cancer pipeline drugs market?
In the Hypopharyngeal Cancer pipeline drugs market the major companies are Boehringer Ingelheim International GmbH, Merck & Co Inc, Eisai Co Ltd, Incyte Corp, Akeso Inc, Ascenta Therapeutics Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Genentech USA Inc, GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co Ltd, and Shanghai Junshi Bioscience Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.